Red and purple may seem like an unconventional color combo, but the hues are totally trending for summer 2026 and they look ...

Diversification isn't about finding one perfect investment; it's about combining complementary holdings that work well ...

Scientific ideas sometimes have to wait decades for technology to catch up. Statistical algorithms developed at the Yerevan ...

The Canucks signed veteran defenceman Jamie Oleksiak to a two-year deal. Steph Chambers / Getty Images It felt like a new day for the rebuilding Vancouver Canucks. In contrast with the damaging, ...

Spread the love“`html Panic attacks can be overwhelming, leaving individuals feeling helpless and afraid. When they strike, ...

Grocery shopping shouldn’t drain your energy — or your bank account. It can be draining to sit down and make a grocery list, but going to the store without a list can also lead to overspending or ...

Quantum computers—devices that process information using quantum mechanical effects—have long been expected to outperform classical systems on certain tasks. Over the past few decades, researchers ...

Another day, another buzzy weight loss strategy. But today’s lesson, the 2-2-2 method for your metabolism, actually entails multiple weight loss techniques like keto, intermittent fasting, ...

(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...

(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...